Table 2.
SF-36 components floor and ceiling effects at 24 months after ICU discharge
| Follow-Up | Whole cohort N = 159 |
Completed recovery N = 61 |
Persistent impairment N = 76 | |||
|---|---|---|---|---|---|---|
| Floor (0) | Ceiling (100) | Floor (0) | Ceiling (100) | Floor (0) | Ceiling (100) | |
| PF | 16 (10) | 9 (6) | 0 (0) | 9 (15)* | 16 (21)* | 0 (0) |
| RP | 71 (45)* | 35(22)* | 9 (15)* | 27 (45)* | 54 (71)* | 3 (4.0) |
| BP | 11 (7) | 52(33)* | 1 (2) | 35 (57)* | 9 (12) | 7 (9.2) |
| GH | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
| XSFMA-F | 29(18)* | 0(0) | 29 (46) | 0(0) | 0(0) | 0(0) |
Data are shown as numbers of patients with percentages. Data of unclustered group (n = 22) not shown (raw data shown in Additional Fig. 2)
PF physical function, RP role physical, BP bodily pain and GH general health, XSFMA-F Extra Short Form Musculoskeletal Function Assessment regarding physical function (F)
*A value of > 15% denoting relevant effects [41]